Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
WAL0921
DRUG
2 trials
Sponsors
Walden Biosciences
Conditions
Diabetic Nephropathies
Healthy
Minimal Change Disease
Primary Focal Segmental Glomerulosclerosis
Primary Immunoglobulin A Nephropathy
Primary Membranous Nephropathy
Phase 1
Single Ascending Dose Study of WAL0921 in Healthy Subjects
Completed
NCT05891366
Walden Biosciences
Healthy
Start: 2023-05-31
End: 2024-01-09
Updated: 2024-04-10
Phase 2
Study of WAL0921 in Patients With Glomerular Kidney Diseases
Recruiting
NCT06466135
Walden Biosciences
Diabetic Nephropathies, Minimal Change Disease, Primary Focal Segmental Glomerulosclerosis +2
Start: 2024-07-02
End: 2027-06-01
Target: 96
Updated: 2026-08-03